We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Make the most of 2022 Lead your own way in business and beyond with our unrivalled journalism.
Add this topic to your myFT Digest for news straight to your inbox
The FT examines the causes and effects of an increasing global resistance to antibiotics: from the pressures doctors are under to prescribe them even for viral infections, to what new treatments are currently in the pipeline, as well as what role can the consumer play in reducing antibiotic use in the food chain
Research underscores the dangers of bacteria developing resistance to antibiotics
Plan B measures such as mask wearing and vaccine passports for large venues will not be renewed after January 26
Top-10 investor Flossbach ‘would strongly oppose’ a deal for consumer business
Departure of Hal Barron comes as pharma group faces pressure to revive drug pipeline
The poor are continuing to bear the brunt of Covid-19
Philanthropist calls on governments to contribute billions to tackle future pathogens and increase vaccine supplies
Hong Kong announces cull of more than 1,000 hamsters amid fears of transmission from pets to humans
Early findings suggest level of antibodies needed to protect against variant ‘too high’ for jab to induce
UK pharma company may still prefer to list its consumer health unit but the bar for success is now higher
French, German and Italian schemes to show proof of vaccination or negative test averted lockdowns
Surge in young patients in England, France and US but the vast majority have mild symptoms
Malaria is constantly present in many places — and still kills hundreds of thousands a year
Investors push for higher price or spin-off after rejecting Unilever’s £50bn offer
Chief executive deSouza attacks regulatory intervention over cancer test company
Hospital beds for children drops by 20% in past five years despite surge in demand
Pharma executive warns policymakers may be incapable of preparing the public for next pandemic
The division jointly owned by Pfizer is due to be spun off in London listing later this year
The consumer goods group would probably have to go higher to win, shouldering heavy debts
Admissions hit record high but some patients are seeking care for reasons unrelated to virus
Global tangle of labour laws and government stances complicate return to the workplace
Aim-listed health tech company says without a loan it is ‘unlikely’ to be able to trade beyond early next month
Ruling marks latest setback for administration as it grapples with spread of Omicron variant
Health service chief in letter to minister queries whether contracts are ‘good value for money’
International Edition
